Ajanta Pharma has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility located in Paithan, Maharashtra. The inspection, conducted from 13 April 2026 to 21 April 2026, has been classified as Voluntary Action Indicated (VAI), signifying a favourable regulatory outcome for the company's facility.

USFDA Inspection Outcome

The VAI classification is one of three possible outcomes assigned by the USFDA following a facility inspection. It indicates that while the agency may have noted certain observations during the inspection process, no regulatory or administrative action is deemed necessary at this stage. This outcome is generally considered a positive result in the pharmaceutical industry, as it confirms the facility's compliance with USFDA standards.

Key Details of the Inspection

The following table summarises the key details related to the USFDA inspection report received by Ajanta Pharma:

Significance of VAI Classification

A Voluntary Action Indicated status from the USFDA reflects that the inspected facility meets the required manufacturing and quality standards as assessed by the regulatory authority. For pharmaceutical companies with US market exposure, receiving a VAI classification on an EIR underscores the facility's adherence to Current Good Manufacturing Practices (cGMP) and supports continued operations for the US market.

Promoter Ravi Agrawal has released the pledge on 1,60,000 equity shares of Ajanta Pharma Limited, reducing the encumbered holdings held by the Ravi Agrawal Trust. The release, attributed to excess pledge, was executed on June 30, 2026, and disclosed to the stock exchanges on the same day. This transaction reduces the trust's total encumbered shares, which were previously pledged for business financing purposes with Infina Finance Private Limited.

The shares were held in the demat account of Barclays Securities (India) Private Limited. The details of the release were submitted in the prescribed format under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing was signed by Ravi Purushottam Agrawal and submitted to BSE Limited and the National Stock Exchange of India.

Prior to this release, Ravi Agrawal, as trustee of the Ravi Agrawal Trust, held 1,697,696 encumbered shares, representing 1.36% of the total share capital of the company. Following the release of 1,60,000 shares, the post-event holding of encumbered shares stands at 1,537,696 shares, which is 1.23% of the total share capital.

The disclosure confirmed that other promoters, including Gabs Investments Pvt Ltd, Yogesh M Agrawal, Mannalal B Agrawal, Rajesh M Agrawal, Aayush M Agrawal, and Ganga Exports, did not report any changes in their encumbrance status during this period.

The following table details the specific release of pledge transaction: